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Varicose veins are a frequently encountered medical condition. In the era of minimally invasive surgery,
several techniques, in the treatment of varicose veins, have been developed in the last few years. One of
the most frequently used new techniques is endovenous laser ablation. Fibrotic sealing of the treated
vein lumen is the ﬁnal result. The vein ablation is obtained under local - tumescent anaesthesia and the
patients can be treated in an ofﬁce setting with immediate return to full activity. Safety and effectiveness
seem to be the major characteristics and advantages of this technique.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Chronic vein insufﬁciency of the lower extremities is one of the
most common benign diseases inWestern countries. It is estimated
that varicose veins in the distribution of the great saphenous vein
(GSV) are present in about 25% of women and 15% of men.1 It seems
that the appearance and evolution of the disease occur due to
multiple factors but mainly the modern lifestyle, characterized by
sedentarity, lack of exercise and obesity.
Surgery is the gold standard in the treatment of varicose veins.
For several decades high ligation at the saphenofemoral junction
(SFJ) and stripping of the GSV was the treatment of choice in order
to eradicate the diseased vein. Insufﬁciency of the small saphenous
vein (SSV) is treated in a similar way, by ligation at the sapheno-
popliteal junction (SPJ) and stripping.
In the last years, in the era of minimally invasive surgery, new
techniques in the treatment of varicose veins, such as the endo-
venous laser ablation (EVLA), have been introduced. In 1999, the
ﬁrst report on EVLA appeared in the literature. Using an 810 - nm
diode laser, Bonè ﬁrst reported the delivery of endoluminal laser
energy for the treatment of the insufﬁcient GSV.2 EVLA of the SSV
was described later.rgery, “Iasò General” Hospital
eece. Tel.: þ30 2107462563;
(G. Galanopoulos).
ciates Ltd. Published by Elsevier Lt2. Mechanism of action
Through laser, which is a form of electromagnetic energy (near
infrared light), a thermal ablation of the treated vein is obtained.
Until now, the laser technology in the treatment of varicose veins
has had a continuous evolution. Any speciﬁc laser is mono-
chromatic, which means that it emits light of a single wavelength.
Several wavelengths have been proposed (810, 940, 980, 1064,
1320, 1470 nm).
The EVLA method of venous closure acts by heat - induced
collagen shrinkage, followed by ﬁbrotic sealing of the vein lumen.
In order to destroy a vein with laser, the vein wall must absorb
enough energy to result in generating so much heat as to damage
all layers of the vein. In case of insufﬁcient energy absorption, the
vein will recanalise. In contrast, if the energy absorbed is excessive,
all the produced heat will dissipate to adjacent tissues with
undesirable damage.3 Experimental studies reveal loss of tunica
intima of the treated vein in the acute phase. Within one month
there is a vein wall thickening with inﬂammatory changes and
presence of ﬁbroblasts, which are responsible for the ﬁbrotic result
of the vein.
It is important for EVLA to minimize thrombus formation. This is
of primary importance in order to avoid recanalisation and thus
recurrence. The tissues contain light absorbing elements, known as
chromophores, such as haemoglobin, myoglobin and interstitial
water. Chromophores absorb light in a speciﬁc range of the elec-
tromagnetic spectrum. The absorption of energy by the chromo-
phores produces a molecular excitation, followed by deexcitation
with releasing of deexcitation energy in the form of heat in thed. All rights reserved.
Fig. 1. The GSV is punctured just below the knee and the guidewire is located within
the vein lumen.
Fig. 2. The correct position of the sheath is controlled.
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ation and thrombus formation. Haemoglobin absorbs part of the
energy emitted by the laser ﬁber, inducing coagulation. The degree
of the absorption depends on the wavelength. The longer the
wavelength is, the less the haemoglobin absorption will be. At
810 nm, which was the ﬁrst wavelength used for the occlusion of
the vein, the absorption by haemoglobinwas much higher than the
absorption by water. At 1470 nm the absorption by water is about
40 times higher than that of haemoglobin.5 Thus, at a longer
wavelength the target of the laser is the veinwall and not the blood.
Having as a target the blood means that the phenomenon of
thrombosis is intense and proportionally the activation of the
thrombolytic system will be equally intense. Consequently, the
possibility of recanalisation will be elevated. On the contrary,
having as a target the water, the amount of energy absorbed by the
blood can be notably diminished and the clot formation may be
weak. This is the reason why the endovenous laser technology
continues moving further toward higher wavelengths. In this way
the haemoglobin absorption is bypassed, allowing more intense
absorption of the laser energy by interstitial water and myoglobin
in the vein wall.5
3. Technique
First of all, the importance of the intraoperative ultrasono-
graphic (US) guidance during the whole procedure must be
underlined. The veinmapping is important at the initial puncture of
the saphenous vein, the advance and the right positioning of the
laser catheter within the vein lumen and at the end, for the eval-
uation of the success of the procedure. Thus, the operator must be
familiar with the ultrasounds.
Access to the saphenous vein is obtained by a needle puncture.
The preferred point of the puncture is just below the knee, because
at this point the diameter of the vein is large and the risk of thermal
injury of the saphenous nerve is low. Sometimes, the vein goes to
spasm and puncture may be difﬁcult. In order to avoid that, many
authors recommend puncturing the veinwithout local anaesthesia,
which can cause the spasm. It is important to put the patient into
the reverse Trendelenburg position previously in order to have
a vein full of blood and make the puncture easier.
Once the access has been obtained under US guidance, a J - tip
guidewire of 0.035 inch. passes through the hollow needle into the
vein lumen [Fig. 1]. Then, the needle is withdrawn and a small
incision is made at the entry point of the guidewire to permit the
passage of the introducer sheath of 5 or 6Fr and the dilator over the
wire. Subsequently, the guidewire and the dilator are removed and
the sheath remains in position [Fig. 2]. Then, the laser ﬁber, which
usually has a diameter of 600 mm is passed through the sheath and
under US guidance is advanced at the SFJ [Figs. 3e4]. The correct
position of the tip of the laser ﬁber is at a distance of 2 cm from the
junction or just below the inferior superﬁcial epigastric vein. This
vein is an important landmark for the positioning of the ﬁber tip in
order to have a safety distance from the femoral vein, avoiding
major complications, such as deep vein thrombosis (DVT). Addi-
tionally, the blood ﬂows from the abdominal wall through the
superﬁcial inferior epigastric vein towards the femoral vein. Thus,
maintaining this vein patent is important for the maintenance of
the patency of the femoral vein.
The procedure can be performed under tumescent anaesthesia
which is administered under US guidance with multiple syringe
hand injections or with the use of a foot pump system. Marking the
vein course with a skin marker could be helpful in the tumescent
solution administration [Fig. 5]. The solution includes 500 mL
saline, 25 mL 2% lidocaine and 10 mLsodium bicarbonate 8,4%. Its
temperature is set at 4 C to cause local anaesthesia and signiﬁcantspasm of the vein. Tumescence is delivered in a circumferential
manner in the perivenous sheath with the use of an 18 - G needle.
The administration of tumescent anaesthesia is of paramount
importance in order to achieve an external compression of the vein,
posing in strict contact the vein wall with the ﬁber tip located
within the lumen and having a direct transmission of the laser
energy to the vein wall. This procedure can also increase the
distance between the vein and the skin,isolating it from the peri-
venous structures and avoiding skin burns. Finally, a painless
procedure is achieved with this kind of anaesthesia, because
tumescence acts as a local anaesthetic. Tumescent solution
excludes blood from the vein by squeezing it out and therefore it is
useful to have the patient in Trendelemburg position during the
administration and start the tumescence distally and proceeding
proximally so that blood does not get trapped. It is useful to
increase the quantity of tumescent solution injected at the level of
the SFJ in order to achieve a better compression of the junction and
avoid a possible extension of a thrombotic phenomenon into the
femoral vein or the passage of bubbles toward the heart.
The parameters of the laser can be adjusted in accordance with
the type of wavelength and the type of ﬁber (bare or radial -
Fig. 5. The laser ﬁber is advanced toward the SFJ and the vein course is marked. This
maneuver is useful in tumescent administration.
Fig. 3. Intraoperative US imaging of the vein is of paramount importance.
G. Galanopoulos, C. Lambidis / International Journal of Surgery 10 (2012) 134e139136
REVIEWemitting ﬁber) used. For example the 1470 nm wavelength closes
successfully the treated veins with a signiﬁcant reduction in
energy.5 There can be used the continuous mode. In the continuous
mode the energy delivered by the vein depends on the pullback
speed and the wattage.6
After setting of the parameters the patient is positioned into the
Trendelenburg position in order to achieve a bloodless vein. This
maneuver in association with the tumescent administration helps
to increase the surface area contact between laser tip and vein wall
and to reduce the amount of blood that can absorb even a small part
of the energy inducing clot formation. Then the laser ﬁber is pulled
back constantly in the case of continuous mode. After complete
withdrawal of the catheter a US examination must be performed to
reveal absence of ﬂow and lack of compression in the treated vein.
At the end of the operation elastic stockings Class II are used in
the treated limbs for two weeks. Patients are mobilized immedi-
ately after the operation and discharged from the hospital or the
ambulatory ofﬁce a few hours later. Postoperative analgesia with
non - steroidal anti - inﬂammatory drugs (NSAIDs) is given to all
patients for a week. The patients return to their normal activities
after two days. The follow - up of the operated patients must be
rigorous. The US and clinical examinations can be performedwithinFig. 4. The laser ﬁber will be introduced, through the sheath, within the vein lumen.the ﬁrst week, at 1, 3, 6 months and then yearly. The patients must
be assessed for lack of ﬂow in the treated vein, recanalisation, DVT
and nerve injury.4. Complications
In the literature the complications after EVLA are very limited.
The most feared complication is DVT. This is the reason for which
some authors recommend the administration of low molecular
weight heparin (LMWH) for a week. The incidence of DVT is vari-
able, nevertheless it remains extremely low (0e5,7%).7 The correct
positioning of the ﬁber tip at a distance of 2 cm from the SFJ
prevents the possible thermal injury at the common femoral vein,
which could result in a thrombotic response. In our practice, by
administrating much more tumescent solution in proximity to the
junction, we obtain a good sealing by the external compression
that, in association with the vein spasm provoked by the cold
tumescent, prevents the damage of the common femoral vein or
the extension of a thrombosis of the saphenous vein to the common
femoral vein. The US examination is recommended to be performed
within the ﬁrst week from the procedure and in case of DVT,
anticoagulation therapy must be started.
Skin burns are another possible complication of this procedure.
The incidence in the overwhelming majority of the studies is
extremely low (<1%).7 This complication can be easily prevented by
the administration of the tumescent solution, which keeps the vein
away from the skin and cools the perivenous tissues. To have
a further protection against that complication some authors
consider in the exclusion criteria for the EVLA a minimum distance
of 4 mm between the skin and the vein. In case of a very superﬁcial
saphenous vein, EVLA should be avoided.
Ecchymosis is the result of microperforations of the vein. These
complications were more frequent when the bare ﬁber with
a forward emission of energy was used. At the advent of the radial
ﬁber with a 360 emission, the energy is distributed homogenously
at the veinwall so microperforations are not so frequent. Generally,
ecchymoses disappear within 1e2 weeks from the procedure. It is
observed that higher wavelengths and continuous mode are asso-
ciated with less ecchymosis.8,9
Nerve injury with paraesthesia and dysaesthesia is another
possible adverse event with an incidence between 0 and 22%7.
Because of the close proximity of the saphenous nerve to the
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is effectuated from just below the knee to the SFJ (at 2 cm from the
junction). Additionally, the tumescent solution along the entire
course of the treated segment of the vein separates the vein from
the perivenous tissues, nerve included. Nerve injury seems to be
more frequent in the case of the SSV treatment, due to anatomical
factors.
Bruising after the procedure occurs at the points of the instil-
lation of tumescent anaesthesia. Generally, it resolves within the
ﬁrst 10 days after the operation.
Superﬁcial thrombophlebitis may be another complication with
an incidence rate that varies from 0 to 25%7, especially in patients
with large side branches of the varicose vein treated. Superﬁcial
thrombophlebitis peaks at 4e7 days and resolves in about a week.
This complication can be prevented by simultaneously performing
the phlebectomies of the branches. The postoperative treatment
with NSAIDs for one week and the use of elastic stockings are very
useful.
5. Limitations and exclusion criteria
There are some patient - related factors that could make EVLA
inappropriate. Anxious patients are generally unsuitable for inter-
ventions in local e tumescent anaesthesia. Patients with peripheral
arterial disease, without peripheral arterial pulse on clinical
examination, where compression bandaging may be improper,
must be excluded. Pregnant and breast feedingwomenmust also be
excluded, because the procedure has not been studied in this cohort
of patients. Besides this, the risk for DVT is generally higher during
pregnancy. The presence of thrombophlebitis can cause technical
difﬁculties because inﬂammation makes the laser ﬁber difﬁcult to
advance at the desired position. Obviously, patients with active or
recent DVT or with a history of pulmonary embolism must be
excluded, such as those with bad general conditions (bedridden).
Anatomical factors could play a role in patient selection. As
mentioned above, treatment of a very superﬁcial GSV or SSV, at 4 or
less mm from the skin, even with appropriate tumescent admin-
istration, could result in skin burns. On the other hand, vein
diameter does not inﬂuence the outcome, if proper tumescent is
injected, because tumescent reduces vein diameter by external
compression. Vein tortuosity may be a limiting factor because of
technical difﬁculties in advancing the guidewire, placing the sheath
and navigating with the laser ﬁber within the tortuous saphenous
vein.
The inﬂuence of oral anticoagulants constitutes another inter-
esting point regarding the success of EVLA. Patients undergoing this
procedure sometimes assume oral anticoagulants for several
comorbidities. It is common practice to interrupt therapy prior to
operation. Thrombosis can be minimized by using higher wave-
lengths. Thus, anticoagulants do not appear to interfere with
ﬁbrotic sealing of the vein. Since EVLA is carried out without inci-
sions (unless there is need for concomitant phlebectomies), taking
oral anticoagulants, such as warfarin, can be continued.10
6. Results
The occlusion of the insufﬁcient saphenous vein is obtained in
a very high percentage. The major part of the published studies
report a success rate of about 100% at a distance of one week after
the procedure. This success rate decreases over time, but remains
over 90% in a large number of case series.8,11e13 It has been shown
that vein occlusion is connected with the amount of energy deliv-
ered by the vein wall.14 When the energy given is low, there is high
probability of reopening or nonocclusion of the vein. Vein
shrinkage seems to fail with delivery of less than 70 J/cm.14e16There are technical errors that can result in inadequate vein wall
heating, such as the rapid withdrawal of the ﬁber (continuous
mode) or the insufﬁcient vein emptying without direct contact of
the laser ﬁber with the vein wall.17 This is important especially for
wavelengths other than 1470 nm, where part of the emitted energy
is absorbed by haemoglobin. In this case, the amount of energy
delivered by the wall of a GSV full of blood can dramatically
decrease.
In the literature the reported rates of recanalisation vary from
0 to 4,8%.18e21 It is accepted that if the amount of energy given is
absorbed by haemoglobin, the thrombotic phenomenon will be
intense and subsequently the risk of recanalisation will be high.
Many authors support that the recanalisation of a vein segment is
improbable in the case that the vein remains occluded at 12
months.17 However, recanalisation of a treated vein has been
reported at 2 and 3 years after EVLA.22 The majority of recurrences
occur within the ﬁrst 3 months.7. EVLA vs stripping and high ligation
Stripping and high ligation of the GSV is a well established
surgical procedure, which has yielded good results. Clinical success
rates in large series vary from 77 to 82%.23,24 This is the reason why
it has been established for many decades as the standard treatment
for patients with GSV reﬂux. On the other hand, EVLA is a relatively
new technique and long e term results in terms of recurrence rates
are still lacking.
Although stripping and ligation of the GSV comprise a “radical
approach” in the treatment of varicose veins, recurrence is not
a rare problem. In the literature, signiﬁcant discrepancies can be
noted in the recurrence rates reported, primarily, because of
differences in the initial treatment and duration of follow e up.
Despite the divergences, the recurrence rate after conventional
surgical treatment remains high, ranging from 26 to 62% during
a period of 3e11 years.25,26 It is supported that clinical and patients’
self e assessment for recurrent varicosities can result in underes-
timation. Recurrences, evaluatedwith duplex imaging, may be even
higher. It is also noteworthy, that about 20% of all varicose vein
interventions are for treating recurrent varicosities.27 Several
factors can be implicated, such as technical failures, diagnostic
errors or inadequate preoperative assessment, progression of
disease, perforator incompetence or accessory vein reﬂux and
mainly because of neovascularisation in the groin.28
Nowadays there is a turn of surgery into less invasive techniques
due to the important beneﬁts shown. First of all EVLA is performed
in local - tumescent anaesthesia and the patient is mobilized
immediately after the procedure. The patient is discharged from
hospital after a few hours. Thus, the procedure can be easily per-
formed in an outpatient setting. Patients can return to normal
activities in 2e3 days.
Stripping and high ligation of the saphenous vein requires
a groin incision, that is avoided in the EVLA. Even a short groin
incision presupposes taking care of thewound until it heals. A groin
incision could be painful and could be the cause of taking analgesics
for some days. With EVLA the groin is not dissected, and the
stimulus for neovascularisation is lacking. The dissection of the
groin with ligation of the tributaries and dissection of the saphe-
nofemoral junction may be sufﬁcient to trigger the phenomenon of
neovascularisation. With EVLA, wound infections in the groin
incision, especially in obese patients, can be avoided.
Ablating the vein to just below the knee abolishes the possibility
of saphenous nerve injury, which is relatively common during
stripping (at the level of the ankle), because of the position of the
nerve in close proximity to the vein mainly in the area of medial
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even pain resistive to analgesics.
Additionally, EVLA in expert hands seems to be a less time
consuming procedure. In terms of health related quality of life,
EVLA has a signiﬁcantly superior effect on the short and long e
term. As described, complications in the EVLA technique are rare
and disturbances, such as post - operative pain or ecchymoses,
seem to be very limited with higher wavelengths and with the
radial ﬁber.
There have been several trials comparing EVLAwith stripping of
the GSV.
Rasmussen et al.29 in a randomized clinical trial compared the
outcomes of 68 limbs treated surgically (stripping of the GSV) and
69 limbs treatedwith EVLA (980 nm diode laser) after a followe up
of 2 years. Both procedures were performed under local tumescent
anaesthesia. This study showed no difference in clinical or ultra-
sound recurrences after these two procedures. Additionally, there
was a similar improvement in quality of life in both groups.
Darwood et al.30 treated 114 limbs with GSV incompetence and
divided them into three groups : 47 limbs received EVLA (810 nm
diode laser) using the pulsed mode, 33 limbs received EVLA using
the continuous mode and the rest 34 limbs were treated surgically.
The principal outcome measures of improvement in disease e
speciﬁc quality of life and elimination of reﬂux were not different
between groups. At 3 months GSV reﬂux was abolished in 94% of
limbs treated with EVLA (both EVLA groups) and in 88% of limbs
treated with stripping and ligation. Return to normal activity and
work following EVLA was quicker.
Carradice et al.31 recruited 280 patients with GSV reﬂux. These
patients were randomized in 2 groups receiving either surgery or
EVLA (810 nm diode laser). Complications were rare in both groups,
but haematoma, infection and sensory disturbance rates were
signiﬁcantly higher after surgical treatment. The surgery group had
a signiﬁcant deterioration in early quality of life, while in the EVLA
group quality of life was preserved. Additionally, the EVLA group
returned to normal activity earlier.
Theivacumar et al.32 in a cohort study compared recurrence
rates and the occurrence of neovascularisation in 118 patients (129
limbs) treated with EVLA (810 nm diode laser) or with stripping
and ligation. Recurrence rates were similar 2 years after treatment
(6,6 vs 7% for surgery and EVLA respectively), but neo-
vascularisation at the SFJ was evident in 1% of EVLA patients
compared with 18% in the surgery group for the same time period.
Patient satisfaction rates were similar in both groups.
Christenson et al.33 randomised patients with GSV insufﬁciency
to surgery (100 limbs) or EVLA (104 limbs). The EVLA ablation was
performed using a 980 nm diode laser. The difference in treatment
failure (recurrence) at 2 years between the two groups did not
reach statistical signiﬁcance. The surgery group had more post-
operative haematomas than EVLA group, but the latter reported
more bruising. Postoperative pain scores were similar between
groups. Similar was also the time they needed to return to normal
activity, mainly because of the more frequent haematomas of the
surgery group and the more frequent bruising of the EVLA patients.
These randomized studies suggest that effectiveness, improve-
ments in disease e speciﬁc quality of life and patient satisfaction
are similar for surgery and EVLA. Return to normal activity and
work in most of the studies occurs earlier after EVLA. On the other
hand, it must be noticed that there are some differences between
the studies. The wavelength used in the EVLA groups is 810 or
980 nm. As explained above, wavelength is a crucial parameter,
because it determines the target of the laser energy given. Thus,
using longer wavelengths a lower recurrence rate is expected.
Another important issue is the amount of energy given in the
treated vein. It is shown that the energy delivery has a determinantrole on recurrence. Lower amount of energy given has worse results
and more frequent recurrences than higher energy doses.15 Thei-
vacumar et al.32 had given <50 J/cm in the recanalised veins and
Darwood et al.30 had given a median amount of energy of 60,6 and
71,1 J per cm treated vein in the 2 EVLA groups. Most of the
abovementioned studies reported similar postoperative pain
between patients of the surgery and EVLA groups. This may be
correlated with the local tumescent anaesthesia administered
(composition and volume of the solution) which is different
between these studies.
Nwaejike et al.34 evaluated the results of EVLA for the treatment
of saphenous vein insufﬁciency. 624 EVLA procedures were per-
formed. General anaesthesia was used in 84% of them and 13% of
the procedures was for recurrent disease. During a median followe
up of 20 months, there were no recurrences or recanalisations of
the treated veins. The complications registered were very limited
(thrombophlebitis 1%, numbness <1% and paraesthesia along the
treated segment <1%). The authors concluded that EVLA is a safe
and effective option in the treatment of GSV or SSV reﬂux and in the
treatment of recurrent varicosities.
8. Ablation of the small saphenous vein
EVLA can be easily applied in the SSV. Conventional surgery for
SSV is related to frequent recurrences and nerve injuries. From
a technical point of view there are some differences between EVLA
of the GSV and SSV.
In the treatment of the SSV the puncture of the vein can bemade
at the level of the lower third of the vein which is usually the most
caudal level of truncal reﬂux. The percutaneous access can be
gained with a micropuncture set under US guidance. A 5F intro-
ducer sheath and a J - tip guidewire are used. The ﬁber tip advances
at a distance of 3e4 cm from the SPJ, which corresponds to the
junction between the interfascial and deep segment of the SSV.35
Keeping at that distance, complications, such as DVT, post-
operative pain, arteriovenous ﬁstula formation, through injury of
the superﬁcial sural artery,36,37 can be avoided. Tumescent anaes-
thesia is applied along the treated vein under US guidance in the
same way as in the treatment of the GSV. The amount of energy
given is about 50 J/cm. A US exam conﬁrms the immediate occlu-
sion of the vein. The patient is mobilized immediately after the
procedure, wearing graduated stockings Class II and is discharged
from hospital after a few hours. The patient has to take NSAIDs for
a week. Follow - up with clinical and US examinations is performed
at 1 week, 1, 3, 6 months and then annually.
9. Coexistence of perforator incompetence
Incompetence of the GSV or the SSV may be accompanied by
perforator incompetence in the territory of the treated vein or at
a lower level. Given the fact that the whole procedure is performed
under US guidance, it is simple localise the incompetent perfora-
tors. Thus, during withdrawal of the laser ﬁber once arriving at the
level of the perforator, one can insist by increasing the energy given
at that point in order to strengthen locally the thermal injury of the
treated vein. The possibility of recanalisation of the GSV or SSV
under the inﬂuence of the incompetent perforators, in this way, can
be minimized. In our experience there is no need for further
treatment.
When the incompetent perforators are localised below the level
of the vein ablation, ligation or concomitant ultrasound e guided
foam sclerotherapy (1e3% polidocanol foam) can be performed.
Undoubtedly the latter confers a much better cosmetic result, but
recanalisation rate at 6 months may be as high as 25%.38 Ligations,
through microe stab incisions, of perforators to sites marked pre e
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approach with an acceptable cosmetic result. Some authors suggest
that the treatment of incompetent perforators should be limited to
those with high volume ﬂow and large diameter.39 EVLA can be
used for treating incompetent perforating veins with an occlusion
rate of 78% at 3 months.4010. Conclusion
Minimally invasive surgery has made advances in several ﬁelds,
such as venous surgery. EVLA appears to be a safe and very effective
technique in the treatment of saphenous vein insufﬁciency and
offers another option besides conventional surgery for treating
varicose veins. EVLA provides signiﬁcantly decreased postoperative
pain and discomfort, sooner return to normal activity than strip-
ping and high ligation and better patient acceptance. Besides all,
nowadays, the use of cost - effective therapies is strongly desirable
in all areas of healthcare and EVLA in ofﬁce setting comprises an
undoubtedly cost - effective solution.Acknowledgements
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